Ashraful I Khan1, Fahima Chowdhury1, Daniel T Leung2, Regina C Larocque3, Jason B Harris3, Edward T Ryan4, Stephen B Calderwood5, Firdausi Qadri6. 1. Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh. 2. Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh; Division of Infectious Diseases, University of Utah, Salt Lake City, UT, USA. 3. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. 4. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA. 5. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA. 6. Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh. Electronic address: fqadri@icddrb.org.
Abstract
BACKGROUND: The objective of this study was to examine the clinical and immunological features of cholera in pregnancy. METHODS: Women of reproductive age presenting to the icddr,b Dhaka hospital with cholera, and enrolled as part of a larger cohort study, were tested for pregnancy on admission. We compared initial clinical features and immune responses of pregnant patients with non-pregnant female patients at days 2, 7 and 21 after infection. RESULTS: Among reproductive age women enrolled between January 2001 and May 2006, 9.7% (14/144) were pregnant. The duration of diarrhoea prior to admission tended to be higher in pregnant compared to non-pregnant patients (p=0.08), but other clinical characteristics did not differ. Antibody responses to cholera toxin B subunit (CtxB), toxin-coregulated pilus A (TcpA), Vibrio cholerae lipopolysaccharide (LPS), and serum vibriocidal antibody responses, were comparable between pregnant and non-pregnant patients. There were no deaths among the pregnant cases or non-pregnant controls, and no adverse foetal outcomes, including stillbirths, during 21 days of follow up of pregnant cases. CONCLUSIONS: To our knowledge, this is the first report of immune responses in pregnant women with cholera. We found that pregnant woman early in pregnancy has comparable clinical illness and subsequent immune responses compared to non-pregnant women. These findings suggest that the evaluation of safety and immunogenicity of oral cholera vaccines in pregnancy should be an area of future investigations.
BACKGROUND: The objective of this study was to examine the clinical and immunological features of cholera in pregnancy. METHODS:Women of reproductive age presenting to the icddr,b Dhaka hospital with cholera, and enrolled as part of a larger cohort study, were tested for pregnancy on admission. We compared initial clinical features and immune responses of pregnant patients with non-pregnant female patients at days 2, 7 and 21 after infection. RESULTS: Among reproductive age women enrolled between January 2001 and May 2006, 9.7% (14/144) were pregnant. The duration of diarrhoea prior to admission tended to be higher in pregnant compared to non-pregnant patients (p=0.08), but other clinical characteristics did not differ. Antibody responses to cholera toxin B subunit (CtxB), toxin-coregulated pilus A (TcpA), Vibrio choleraelipopolysaccharide (LPS), and serum vibriocidal antibody responses, were comparable between pregnant and non-pregnant patients. There were no deaths among the pregnant cases or non-pregnant controls, and no adverse foetal outcomes, including stillbirths, during 21 days of follow up of pregnant cases. CONCLUSIONS: To our knowledge, this is the first report of immune responses in pregnant women with cholera. We found that pregnant woman early in pregnancy has comparable clinical illness and subsequent immune responses compared to non-pregnant women. These findings suggest that the evaluation of safety and immunogenicity of oral cholera vaccines in pregnancy should be an area of future investigations.
Authors: Muhammad Asaduzzaman; Edward T Ryan; Manohar John; Long Hang; Ashraful I Khan; A S G Faruque; Ronald K Taylor; Stephen B Calderwood; Firdausi Qadri Journal: Infect Immun Date: 2004-08 Impact factor: 3.441
Authors: Debasish Saha; Regina C LaRocque; Ashraful I Khan; Jason B Harris; Yasmin Ara Begum; Syed M Akramuzzaman; Abu S G Faruque; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood Journal: J Infect Dis Date: 2004-05-25 Impact factor: 5.226
Authors: Lisa M Christian; Kyle Porter; Erik Karlsson; Stacey Schultz-Cherry; Jay D Iams Journal: Am J Reprod Immunol Date: 2013-04-01 Impact factor: 3.886
Authors: Daniel T Leung; Taher Uddin; Peng Xu; Amena Aktar; Russell A Johnson; Mohammad Arif Rahman; Mohammad Murshid Alam; Meagan Kelly Bufano; Grace Eckhoff; Ying Wu-Freeman; Yanan Yu; Tania Sultana; Farhana Khanam; Amit Saha; Fahima Chowdhury; Ashraf I Khan; Richelle C Charles; Regina C Larocque; Jason B Harris; Stephen B Calderwood; Pavol Kovác; Firdausi Qadri; Edward T Ryan Journal: Clin Vaccine Immunol Date: 2013-03-20
Authors: Natalie G Exum; Nora Pisanic; Douglas A Granger; Kellogg J Schwab; Barbara Detrick; Margaret Kosek; Andrey I Egorov; Shannon M Griffin; Christopher D Heaney Journal: Curr Environ Health Rep Date: 2016-09
Authors: Kira L Newman; Kathryn Gustafson; Janet A Englund; Amalia Magaret; Subarna Khatry; Steven C LeClerq; James M Tielsch; Joanne Katz; Helen Y Chu Journal: Open Forum Infect Dis Date: 2019-01-14 Impact factor: 3.835
Authors: Abu S G Faruque; Azharul Islam Khan; S M Rafiqul Islam; Baitun Nahar; M Nasif Hossain; Yulia Widiati; A S M Mainul Hasan; Mukeshkumar Prajapati; Minjoon Kim; Maya Vandenent; Tahmeed Ahmed Journal: PLoS One Date: 2021-08-02 Impact factor: 3.240